Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

The switch from buprenorphine to tapentadol: is it worth?

Miclescu A.

Rom J Anaesth Intensive Care. 2016 Oct;23(2):133-139. doi: 10.21454/rjaic.7518/232.bup. Review.

2.

No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.

Kosloski MP, Zhao W, Asatryan A, Kort J, Geoffroy P, Liu W.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00958-17. doi: 10.1128/AAC.00958-17. Print 2017 Oct.

PMID:
28807904
3.

Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications.

Bednasz CJ, Venuto CS, Ma Q, Morse GD.

Clin Pharmacol Drug Dev. 2017 Mar;6(2):135-139. doi: 10.1002/cpdd.313.

PMID:
28263465
4.

Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects.

Hagelberg NM, Fihlman M, Hemmilä T, Backman JT, Laitila J, Neuvonen PJ, Laine K, Olkkola KT, Saari TI.

Pharmacol Res Perspect. 2016 Nov 3;4(6):e00271. doi: 10.1002/prp2.271. eCollection 2016 Dec.

5.

Use of an Acetyl Derivative to Improve GC-MS Determination of Norbuprenorphine in the Presence of High Concentrations of Buprenorphine in Urine.

Gervais JR, Hobbs GA.

J Anal Toxicol. 2016 Apr;40(3):208-12. doi: 10.1093/jat/bkw001. Epub 2016 Jan 25.

6.

Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain.

Khanna IK, Pillarisetti S.

J Pain Res. 2015 Dec 4;8:859-70. doi: 10.2147/JPR.S85951. eCollection 2015. Review.

7.

Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone.

Garimella T, Wang R, Luo WL, Wastall P, Kandoussi H, DeMicco M, Bruce RD, Hwang C, Bertz R, Bifano M.

Antimicrob Agents Chemother. 2015 Sep;59(9):5503-10. doi: 10.1128/AAC.00478-15. Epub 2015 Jun 29.

8.

New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.

Soyka M.

Subst Abuse Rehabil. 2015 Jan 6;6:1-14. doi: 10.2147/SAR.S45585. eCollection 2015. Review.

9.

Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Greenwald MK, Comer SD, Fiellin DA.

Drug Alcohol Depend. 2014 Nov 1;144:1-11. doi: 10.1016/j.drugalcdep.2014.07.035. Epub 2014 Aug 19. Review.

10.

Effect of Animal Condition and Fluvoxamine on the Result of [(18)F]N-3-Fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) Nortropane ([(18)F]FP-CIT) PET Study in Mice.

Shin KH, Park SA, Kim SY, Lee SJ, Oh SJ, Kim JS.

Nucl Med Mol Imaging. 2012 Mar;46(1):27-33. doi: 10.1007/s13139-011-0117-5. Epub 2011 Nov 26.

11.

A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.

Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH.

Expert Rev Clin Pharmacol. 2013 May;6(3):249-69. doi: 10.1586/ecp.13.18. Review.

12.

Pharmacokinetics of 2 formulations of buprenorphine in macaques (Macaca mulatta and Macaca fascicularis).

Nunamaker EA, Halliday LC, Moody DE, Fang WB, Lindeblad M, Fortman JD.

J Am Assoc Lab Anim Sci. 2013 Jan;52(1):48-56.

13.

Reduced pupil diameter in volunteers on stable buprenorphine maintenance therapy with telaprevir: a drug-drug interaction involving p-glycoprotein at the blood-brain barrier?

Mégarbane B, Alhaddad H, Declèves X.

Antimicrob Agents Chemother. 2012 Nov;56(11):6070. doi: 10.1128/AAC.01295-12. No abstract available.

14.

Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.

Brown SM, Holtzman M, Kim T, Kharasch ED.

Anesthesiology. 2011 Dec;115(6):1251-60. doi: 10.1097/ALN.0b013e318238fea0.

15.

Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.

Mitra P, Venitz J, Yuan Y, Zhang Y, Gerk PM.

Drug Metab Dispos. 2011 Sep;39(9):1589-96. doi: 10.1124/dmd.111.038588. Epub 2011 Jun 17.

16.

Gender differences in pharmacokinetics of maintenance dosed buprenorphine.

Moody DE, Fang WB, Morrison J, McCance-Katz E.

Drug Alcohol Depend. 2011 Nov 1;118(2-3):479-83. doi: 10.1016/j.drugalcdep.2011.03.024. Epub 2011 Apr 23.

17.

Effects of buprenorphine, meloxicam, and flunixin meglumine as postoperative analgesia in mice.

Tubbs JT, Kissling GE, Travlos GS, Goulding DR, Clark JA, King-Herbert AP, Blankenship-Paris TL.

J Am Assoc Lab Anim Sci. 2011 Mar;50(2):185-91.

18.

Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment.

McLachlan AJ, Bath S, Naganathan V, Hilmer SN, Le Couteur DG, Gibson SJ, Blyth FM.

Br J Clin Pharmacol. 2011 Mar;71(3):351-64. doi: 10.1111/j.1365-2125.2010.03847.x. Review.

19.

(R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy.

Gordon AL, Lopatko OV, Somogyi AA, Foster DJ, White JM.

Br J Clin Pharmacol. 2010 Dec;70(6):895-902. doi: 10.1111/j.1365-2125.2010.03759.x.

20.

Sustained release d-amphetamine reduces cocaine but not 'speedball'-seeking in buprenorphine-maintained volunteers: a test of dual-agonist pharmacotherapy for cocaine/heroin polydrug abusers.

Greenwald MK, Lundahl LH, Steinmiller CL.

Neuropsychopharmacology. 2010 Dec;35(13):2624-37. doi: 10.1038/npp.2010.175. Epub 2010 Sep 29.

Supplemental Content

Support Center